Status:
COMPLETED
Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis
Lead Sponsor:
Sanofi
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
All Genders
6-11 years
Phase:
PHASE4
Brief Summary
To determine the safety and efficacy of Fexofenadine (Telfast®) 30mg pediatric tablets on Filipino children aged 6 to 11 for the relief of symptoms associated with perennial and intermittent allergic ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Children who manifest allergic rhinitis symptoms such as sneezing, rhinorrhea, itchy nose/palate/throat and/or itchy/watery/red eyes.
Exclusion
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT00741897
Start Date
March 1 2002
Last Update
September 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-aventis administrative office
Makati City, Philippines